SCHEMBL718632

SCHEMBL718632

CCCCCCC(Nc1ccc(C(=O)NCCC(=O)OCC)cc1)c1oc2ccc(OC)cc2c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.42
APP P05067 1/20 0.41
ADCY6 O43306 2/20 0.40
ADCY3 O60266 2/20 0.40
ADCY9 O60503 2/20 0.40
ADCY5 O95622 2/20 0.40
ADCY8 P40145 2/20 0.40
GCGR P47871 2/20 0.40
ADCY7 P51828 2/20 0.40
ADCY2 Q08462 2/20 0.40
ADCY1 Q08828 2/20 0.40
ADCY4 Q8NFM4 2/20 0.40
KMT2A Q03164 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719312 0.94 SMN1; SMN2 (0.45) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL717999 0.92 GCGR (0.47) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL719143 0.92 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL720233 0.88 KDM4E (0.49) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL720030 0.86 KMT2A (0.43) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL717086 0.85 NPC1 (0.46) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL720932 0.85 KDM4E (0.43) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL721304 0.85 MAPT (0.45) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL3402158 0.85 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL3396979 0.83 NPC1 (0.45) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885SMN1; SMN2 1051/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885SMN1; SMN2 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.